Treatment of lung cancer carrier of epidermal growth factor receptor mutation
Keywords:
efficacy, lung neoplasms, protein tyrosine kinases, survival.Abstract
Introduction: Lung cancer continues to be a health problem worldwide. In non-small cell lung carcinoma has been analyzed and the presence of a series of molecular alterations has been identified, such as: the mutation of the epidermal growth factor receptor.Objective: Describe the development and evolution of tyrosine kinase inhibitors for the treatment of patients with epidermal growth factor receptor-mutated non small cell lung cancer.
Methods: A literature review article was carried out, in which EMBASE, Cochrane and Scopus databases were consulted, as well as PubMed platform. Medical Subject Headings (MeSH) terms were used, articles published between 2014 and 2023, in spanish and English language, were taken into account. Overall, 183 articles were reviewed and 52 were selected: review articles (16) and original articles (36), textbooks (2) and diagnosis and treatment guide (2).
Development: The discovery of this gene was followed by development tyrosine kinase inhibitor drug, which has demonstrating greater effectiveness, in patients carrying this mutation compared to chemotherapy, which began a new era in the treatment of lung cancer. In spite of excellent response rates and survival, most patients develop acquired resistance after a median survival of 12 months after starting treatment.
Conclusions: Epidermal growth factor receptor mutation target therapies changed the standard of treatment of lung cancer patients who express this mutation.
Downloads
Download data is not yet available.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataran I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 cancers in 185 countries [Internet]. CA Cancer J Clin. 2021; 71(3):209-49. DOI: 10.3322/caac.21660
2. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non- small cell lung cancer: Past, present and future [Internet]. World J Clin Oncol. 2021; 12(4):217-37. DOI: 10.5306/wjco.v12.i4.217
3. DeVita VT, Rosenberg SA, Lawrence TS. Cancer Principles & Practice of Oncology. Primer of the molecular biology of cáncer. Third edition. Philadelphia: Editorial Wolters Kluwer; 2021.
4.Wadowska K, Bil-Lula I, Trembecki L, Sliwinska-Mosson M. Genetic markers in lung cancer diagnosis: a review [Internet]. Int J Mol Sci. 2020; 21(13):4569. DOI: 10.3390/ijms21134569
5. Herrera-Juarez M, Serrano-Gomez C, Bote de Cabo H, Paz-Ares L. Targer therapy for lung cáncer: beyong EGFR and ALK [Internet]. Cancer. 2023; 129(12):1803-20. DOI: 10.1002/cncr.34757
6. Zheng R, Yin Z, Alhatem A, Lyle D, You B, Jiang A, et al. Epidemiologic features of NSCLC gene alterations in Hispanic patients from Puerto Rico [Internet]. Cancers. 2020; 12(12):3492. DOI: 10.3390/cancers12123492
7. Niederhuber J, Armitage J, Doroshow J, Kastan M, Teper J. Abeloff. Oncologíaclínica. 6th edition. España. Editorial Elsevier; 2020.
8. Hubbard SR. EGF receptor inhibition: Attacks on multiple fronts [Internet]. Cancer Cell. 2005; 7(4):287-8. DOI: 10.1016/j.ccr.2005.04.004
9. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al . Epidermal growth factor receptor (EGFR) signaling in cancer [Internet]. Gene. 2006; 366(1):2-16. DOI: 10.106/j.gene.2005.10.018
10. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy [Internet]. Nat Rev Cancer. 2004; 4(5):361-70. DOI: 10.1038/nrc1360
11. Dalurzo M, Aviles-Salas A, Soares F, HouY, Li Y, Stroganova A, et al. Testing for EGFR mutations and ALK rearrangements in Advanced Non Small Cell Lung Cancer. Considerations for countries in emerging markets [Internet]. Onco Targets and Therapy. 2021; 14:4671-92. DOI: 10.2147/OTT.S313669
12. Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, et al. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests [Internet]. Clin Lung Cancer. 2020; 21(3):e182-e190. DOI: 10.1016/j.cllc.2019.11.006
13. Rao S, Anthony M, Chowdhry N, Kathrotia R, Mishra M, Naithani M, et al. Molecular Characterization of Lung carcinomas: a study on diagnosis, predictive and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India [Internet]. J Carcinog. 2021; 20:17. DOI: 10.4103/jcar_14_21
14. Thomas R,Weihua Z.Rethink of EGFR in Cancer With Its Kinase Independent Function on Board [Internet]. Front Oncol. 2019; 9:800. DOI: 10.3389/fonc.2019.00800
15. Abourehab M, Alqahtani A, Youssif B, Gouda A. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism [Internet]. Molecules. 2021; 26(21):6677. DOI: 10.3390/molecules26216677
16. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Geftinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma [Internet]. N Engl J Med. 2009; 361(10):947-957. DOI: 10.1056/NEJMoa0810699
17. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinomaof the lung [Internet]. J ClinOncol. 2012; 30(10):1122-28. DOI: 10.1200/JCO.2011.36.8456
18. Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatino with docetaxel as the first-line treatment for patients with IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer [Internet]. Ann Oncol. 2019; 30(12):1978-84. DOI: 10.1093/annoncol/mdz399
19. Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight [Internet]. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188967. DOI: 10.1016/j.bbcan.2023.188967
20. Lu HL, Jie GL, Wu YL. Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials [Internet].
Expert Opin Emerg Drugs. 2022; 27(2):111-26. DOI: 10.1080/14728214.2022.2063836
21. Cáceres H, Varona L, Nenínger E, Basanta D, Duvergel D, Carrillo C, et al. Tratamiento con inhibidores tirosina cinasa en pacientes con cáncer de pulmón [Internet]. Rev Cub de Oncol. 2022 [acceso: 22/12/2023]; 20(1):e173. Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/173
22. Zhou C, Wu YL, Chen G, Feng J, Liu X, Wang Ch, et al. Erlotinib versus chemotherapy as first -line treatment for patients with advanced EGFR mutation-positive non small- cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open label, randomized, phase III study [Internet]. Lancert Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X
23. Rosell R, Caecereny E, Gervais R, Vergnenegre A, Massuti B, FelipE, et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation- positive non- small cell lung cancer (EURTAC): a multicenter, open -label, randomized phase 3 trial [Internet]. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X
24. Miller V, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W, et al. Afatinib versus placebo for patients with advanced, metastatic non-small cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX- Lung 1): a phase 2b/3 randomisedtrial [Internet]. Lancet Oncol. 2012; 13(5):528-38. DOI: 10.1016/S1470-2045(12)70087-6
25.Yang J, Wu Y-L, Shuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatino-based chemotherapy for egfr mutation -positive lung adenocarcinoma (Lux-Lung 3 and Lux-Lung 6): analysis of overall survival data from two randomised, phase 3 trial [Internet]. Lancet Oncol. 2015; 16(2):141-51. DOI: 10.1016/S1470-2045(14)71173-8
26. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, MokT,etal.Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [Internet]. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X
27. Tu HY, Wu YL. Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data [Internet]. Futur Oncol. 2020; 16(31):2569-86. DOI: 10.2217/fon-2020-0320
28. Janne PA, Ou SH, Kim DW, Oxnard G, Martins R, Kris M,et al. Dacomitinib as first -line treatment in patients with clinically or molecularly selected advanced non -small cell lung cancer: a multicenter, open- label, phase 2 trial [Internet]. Lancet Oncol. 2014; 15(13):1433-41. DOI: 10.1016/S1470-2045(14)70461-9
29. Wu Y, Cheng Y, Zhou X, Lee K, NakagawaK, Niho S, et al. Dacomitinb versus Gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small cell lung cancer (ARCHER 1050): a randomised, open -label, phase 3 trial [Internet]. Lancet Oncol. 2017; 18(11):1454-66. DOI: 10.1016/S1470-2045(17)30608-3
30. Mok T, Wu YL, Ahn MJ, Garassino M, Kim H, Ramalingam S,et al. Osimertinib or Platinum- pemetrexed in EGFR T790M positive lung cancer [Internet]. NEnglJ Med. 2017; 376(7):629-40. DOI: https://doi.org/10.1056/NEJMoa1612674
31. Popat S, Ahn MJ, Leighl NB, Ramalinga S, Reungwetwattana T, Sira S, et al. Osimertinib for EGFR-mutant non- small cell lung cancer central nervous system metastases: current evidence and future perspertives on therapeutic strategies [Internet]. Target Oncol. 2023; 18(1):9-24. DOI: 10.1007/s11523-022-00941-7
32. Lee JH, Kim EY, Park CK, Lee SY, Lee MK, Yoon SH, et al. Real-World Study of Osimertinib in Korean Patients with Epidermal GrowthFactor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer [Internet]. Cancer Res Treat. 2023; 55(1):112-22. DOI: 10.4143/crt.2022.381
33. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFRMutated Advanced Non-SmallCell Lung Cancer [Internet]. N Eng J Med. 2018; 378(2):11325. DOI: 10.1056/NEJMoa1713137
34. Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [Internet]. NEngl J Med. 2020; 382(1):41-50. DOI: 10.1056/NEJMoa1913662
35. Hung YL, LiuH, Wampfler JA, Tazelaar HD, LiY, Peikert T, et al. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation [Internet]. J Cancer Res Clin Oncol. 2022; 148(8):2099-114. DOI: 10.1007/s00432-021-03766-5
36. Viray H, Vallillo AP, Widick P, Academia E, Shea M, Rangachari D, et al. A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib [Internet]. J Clin Oncol. 2022; 40(16):e21033-e21033.DOI: 10.1200/JCO.2022.40
37. Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data [Internet]. Drugs - Real World Outcomes. 2022; 9(3):333-45. DOI: 10.1007/s40801-022-00302-w
38. Li X, Zhai Z, Zhu Y, Zhou H. Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation [Internet]. Pak J Med Sci. 2022; 38(6):1589-94. DOI: 10.12669/pjms.38.6.5456
39. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer [Internet]. N Engl J Med. 2020; 383(18):1711-23. DOI: 10.1056/NEJMoa2027071
40. Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research [Internet]. Pharmacol Res. 2021; 167:105583. DOI: 10.1016/j.phrs.2021.105583
41. Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies [Internet]. Cancers (Basel). 2022; 14(14):3337. DOI: 10.3390/cancers14143337
42. Han X, Liang L, He C, Ren Q, Su J, Cao L, et al. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma [Internet]. BMC Complement Med Ther. 2023; 23(1):422. DOI: 10.1186/s12906-023-04213-3
43. Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn J, et al. Genomic Landscape of Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR T790M-Mutant Non-Small Cell Lung Cancer [Internet]. Cancer. 2020; 126(11):2704-12. DOI: 10.1002/cncr.32809
44. Park HR, Kim T, Lee Y, Kim S, Park S, Ju Y et al. Acquired resistance to third-generationEGFR T790M mutant NSCLC [Internet]. J Thorac Oncol. 2021; 16(11):1859-71. DOI: 10.1016/j.jtho.2021.06.013
45. Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, et al. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells [Internet]. Cancer Med. 2022; 11(4):944-55. DOI: 10.1002/cam4.4504
46. Yao Y, Yang H, Zhu B, Wang S, Pang J, Wu X, et al. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non- small-cell lung cancer [Internet]. Respir Res. 2023; 24(1):28. DOI: 10.1186/s12931-023-02329-1
47. Kang J, Deng QM, Feng W, Chen ZH, Su JW, Chen HJ,et al. Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer [Internet]. Lung Cancer. 2023; 178:66-74. DOI: 10.1016/j.lungcan.2023.01.017
48. Pasaro A, Janne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR- mutant lung cancer [Internet]. Nat Cancer. 2021; 2(4):377-91. DOI: 10.1038/s43018-021-00195-8
49. He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer [Internet]. Int J Oncol. 2021; 59(5):90. DOI: 10.3892/ijo.2021.5270
50. Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer [Internet]. Cancers (Basel). 2023; 15(2):504. DOI: 10.3390/cancers15020504
51. Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Macciò A. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment [Internet]. Int J Mol Sci. 2022; 23(12):6489. DOI: 10.3390/ijms23126489
52. Flores YI, Neninger E, Páramo DL, Ortiz RA, Alfonso S, Alsina SC, et al. Diagnóstico y tratamiento del cáncer de pulmón. Programa Integral para el control del Cáncer en Cuba. La Habana: Editorial Ciencias Médicas; 2020.
53. Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR,et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2024; 22(4):249-274. DOI: 10.6004/jnccn.2204.0023
54. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. ESMO Guidelines Committee.Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [Internet]. Ann Oncol. 2023; 34(4):339-57. DOI: 10.1016/j.annonc.2022.12.009
55. Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy [Internet]. Ann Oncol. 2021; 32(12):1637-42. DOI: 10.1016/j.annonc.2021.08.1994
2. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non- small cell lung cancer: Past, present and future [Internet]. World J Clin Oncol. 2021; 12(4):217-37. DOI: 10.5306/wjco.v12.i4.217
3. DeVita VT, Rosenberg SA, Lawrence TS. Cancer Principles & Practice of Oncology. Primer of the molecular biology of cáncer. Third edition. Philadelphia: Editorial Wolters Kluwer; 2021.
4.Wadowska K, Bil-Lula I, Trembecki L, Sliwinska-Mosson M. Genetic markers in lung cancer diagnosis: a review [Internet]. Int J Mol Sci. 2020; 21(13):4569. DOI: 10.3390/ijms21134569
5. Herrera-Juarez M, Serrano-Gomez C, Bote de Cabo H, Paz-Ares L. Targer therapy for lung cáncer: beyong EGFR and ALK [Internet]. Cancer. 2023; 129(12):1803-20. DOI: 10.1002/cncr.34757
6. Zheng R, Yin Z, Alhatem A, Lyle D, You B, Jiang A, et al. Epidemiologic features of NSCLC gene alterations in Hispanic patients from Puerto Rico [Internet]. Cancers. 2020; 12(12):3492. DOI: 10.3390/cancers12123492
7. Niederhuber J, Armitage J, Doroshow J, Kastan M, Teper J. Abeloff. Oncologíaclínica. 6th edition. España. Editorial Elsevier; 2020.
8. Hubbard SR. EGF receptor inhibition: Attacks on multiple fronts [Internet]. Cancer Cell. 2005; 7(4):287-8. DOI: 10.1016/j.ccr.2005.04.004
9. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al . Epidermal growth factor receptor (EGFR) signaling in cancer [Internet]. Gene. 2006; 366(1):2-16. DOI: 10.106/j.gene.2005.10.018
10. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy [Internet]. Nat Rev Cancer. 2004; 4(5):361-70. DOI: 10.1038/nrc1360
11. Dalurzo M, Aviles-Salas A, Soares F, HouY, Li Y, Stroganova A, et al. Testing for EGFR mutations and ALK rearrangements in Advanced Non Small Cell Lung Cancer. Considerations for countries in emerging markets [Internet]. Onco Targets and Therapy. 2021; 14:4671-92. DOI: 10.2147/OTT.S313669
12. Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, et al. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests [Internet]. Clin Lung Cancer. 2020; 21(3):e182-e190. DOI: 10.1016/j.cllc.2019.11.006
13. Rao S, Anthony M, Chowdhry N, Kathrotia R, Mishra M, Naithani M, et al. Molecular Characterization of Lung carcinomas: a study on diagnosis, predictive and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India [Internet]. J Carcinog. 2021; 20:17. DOI: 10.4103/jcar_14_21
14. Thomas R,Weihua Z.Rethink of EGFR in Cancer With Its Kinase Independent Function on Board [Internet]. Front Oncol. 2019; 9:800. DOI: 10.3389/fonc.2019.00800
15. Abourehab M, Alqahtani A, Youssif B, Gouda A. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism [Internet]. Molecules. 2021; 26(21):6677. DOI: 10.3390/molecules26216677
16. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Geftinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma [Internet]. N Engl J Med. 2009; 361(10):947-957. DOI: 10.1056/NEJMoa0810699
17. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinomaof the lung [Internet]. J ClinOncol. 2012; 30(10):1122-28. DOI: 10.1200/JCO.2011.36.8456
18. Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatino with docetaxel as the first-line treatment for patients with IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer [Internet]. Ann Oncol. 2019; 30(12):1978-84. DOI: 10.1093/annoncol/mdz399
19. Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight [Internet]. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188967. DOI: 10.1016/j.bbcan.2023.188967
20. Lu HL, Jie GL, Wu YL. Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials [Internet].
Expert Opin Emerg Drugs. 2022; 27(2):111-26. DOI: 10.1080/14728214.2022.2063836
21. Cáceres H, Varona L, Nenínger E, Basanta D, Duvergel D, Carrillo C, et al. Tratamiento con inhibidores tirosina cinasa en pacientes con cáncer de pulmón [Internet]. Rev Cub de Oncol. 2022 [acceso: 22/12/2023]; 20(1):e173. Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/173
22. Zhou C, Wu YL, Chen G, Feng J, Liu X, Wang Ch, et al. Erlotinib versus chemotherapy as first -line treatment for patients with advanced EGFR mutation-positive non small- cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open label, randomized, phase III study [Internet]. Lancert Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X
23. Rosell R, Caecereny E, Gervais R, Vergnenegre A, Massuti B, FelipE, et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation- positive non- small cell lung cancer (EURTAC): a multicenter, open -label, randomized phase 3 trial [Internet]. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X
24. Miller V, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W, et al. Afatinib versus placebo for patients with advanced, metastatic non-small cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX- Lung 1): a phase 2b/3 randomisedtrial [Internet]. Lancet Oncol. 2012; 13(5):528-38. DOI: 10.1016/S1470-2045(12)70087-6
25.Yang J, Wu Y-L, Shuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatino-based chemotherapy for egfr mutation -positive lung adenocarcinoma (Lux-Lung 3 and Lux-Lung 6): analysis of overall survival data from two randomised, phase 3 trial [Internet]. Lancet Oncol. 2015; 16(2):141-51. DOI: 10.1016/S1470-2045(14)71173-8
26. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, MokT,etal.Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [Internet]. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X
27. Tu HY, Wu YL. Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data [Internet]. Futur Oncol. 2020; 16(31):2569-86. DOI: 10.2217/fon-2020-0320
28. Janne PA, Ou SH, Kim DW, Oxnard G, Martins R, Kris M,et al. Dacomitinib as first -line treatment in patients with clinically or molecularly selected advanced non -small cell lung cancer: a multicenter, open- label, phase 2 trial [Internet]. Lancet Oncol. 2014; 15(13):1433-41. DOI: 10.1016/S1470-2045(14)70461-9
29. Wu Y, Cheng Y, Zhou X, Lee K, NakagawaK, Niho S, et al. Dacomitinb versus Gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small cell lung cancer (ARCHER 1050): a randomised, open -label, phase 3 trial [Internet]. Lancet Oncol. 2017; 18(11):1454-66. DOI: 10.1016/S1470-2045(17)30608-3
30. Mok T, Wu YL, Ahn MJ, Garassino M, Kim H, Ramalingam S,et al. Osimertinib or Platinum- pemetrexed in EGFR T790M positive lung cancer [Internet]. NEnglJ Med. 2017; 376(7):629-40. DOI: https://doi.org/10.1056/NEJMoa1612674
31. Popat S, Ahn MJ, Leighl NB, Ramalinga S, Reungwetwattana T, Sira S, et al. Osimertinib for EGFR-mutant non- small cell lung cancer central nervous system metastases: current evidence and future perspertives on therapeutic strategies [Internet]. Target Oncol. 2023; 18(1):9-24. DOI: 10.1007/s11523-022-00941-7
32. Lee JH, Kim EY, Park CK, Lee SY, Lee MK, Yoon SH, et al. Real-World Study of Osimertinib in Korean Patients with Epidermal GrowthFactor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer [Internet]. Cancer Res Treat. 2023; 55(1):112-22. DOI: 10.4143/crt.2022.381
33. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFRMutated Advanced Non-SmallCell Lung Cancer [Internet]. N Eng J Med. 2018; 378(2):11325. DOI: 10.1056/NEJMoa1713137
34. Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [Internet]. NEngl J Med. 2020; 382(1):41-50. DOI: 10.1056/NEJMoa1913662
35. Hung YL, LiuH, Wampfler JA, Tazelaar HD, LiY, Peikert T, et al. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation [Internet]. J Cancer Res Clin Oncol. 2022; 148(8):2099-114. DOI: 10.1007/s00432-021-03766-5
36. Viray H, Vallillo AP, Widick P, Academia E, Shea M, Rangachari D, et al. A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib [Internet]. J Clin Oncol. 2022; 40(16):e21033-e21033.DOI: 10.1200/JCO.2022.40
37. Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data [Internet]. Drugs - Real World Outcomes. 2022; 9(3):333-45. DOI: 10.1007/s40801-022-00302-w
38. Li X, Zhai Z, Zhu Y, Zhou H. Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation [Internet]. Pak J Med Sci. 2022; 38(6):1589-94. DOI: 10.12669/pjms.38.6.5456
39. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer [Internet]. N Engl J Med. 2020; 383(18):1711-23. DOI: 10.1056/NEJMoa2027071
40. Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research [Internet]. Pharmacol Res. 2021; 167:105583. DOI: 10.1016/j.phrs.2021.105583
41. Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies [Internet]. Cancers (Basel). 2022; 14(14):3337. DOI: 10.3390/cancers14143337
42. Han X, Liang L, He C, Ren Q, Su J, Cao L, et al. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma [Internet]. BMC Complement Med Ther. 2023; 23(1):422. DOI: 10.1186/s12906-023-04213-3
43. Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn J, et al. Genomic Landscape of Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR T790M-Mutant Non-Small Cell Lung Cancer [Internet]. Cancer. 2020; 126(11):2704-12. DOI: 10.1002/cncr.32809
44. Park HR, Kim T, Lee Y, Kim S, Park S, Ju Y et al. Acquired resistance to third-generationEGFR T790M mutant NSCLC [Internet]. J Thorac Oncol. 2021; 16(11):1859-71. DOI: 10.1016/j.jtho.2021.06.013
45. Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, et al. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells [Internet]. Cancer Med. 2022; 11(4):944-55. DOI: 10.1002/cam4.4504
46. Yao Y, Yang H, Zhu B, Wang S, Pang J, Wu X, et al. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non- small-cell lung cancer [Internet]. Respir Res. 2023; 24(1):28. DOI: 10.1186/s12931-023-02329-1
47. Kang J, Deng QM, Feng W, Chen ZH, Su JW, Chen HJ,et al. Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer [Internet]. Lung Cancer. 2023; 178:66-74. DOI: 10.1016/j.lungcan.2023.01.017
48. Pasaro A, Janne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR- mutant lung cancer [Internet]. Nat Cancer. 2021; 2(4):377-91. DOI: 10.1038/s43018-021-00195-8
49. He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer [Internet]. Int J Oncol. 2021; 59(5):90. DOI: 10.3892/ijo.2021.5270
50. Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer [Internet]. Cancers (Basel). 2023; 15(2):504. DOI: 10.3390/cancers15020504
51. Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Macciò A. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment [Internet]. Int J Mol Sci. 2022; 23(12):6489. DOI: 10.3390/ijms23126489
52. Flores YI, Neninger E, Páramo DL, Ortiz RA, Alfonso S, Alsina SC, et al. Diagnóstico y tratamiento del cáncer de pulmón. Programa Integral para el control del Cáncer en Cuba. La Habana: Editorial Ciencias Médicas; 2020.
53. Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR,et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2024; 22(4):249-274. DOI: 10.6004/jnccn.2204.0023
54. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. ESMO Guidelines Committee.Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [Internet]. Ann Oncol. 2023; 34(4):339-57. DOI: 10.1016/j.annonc.2022.12.009
55. Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy [Internet]. Ann Oncol. 2021; 32(12):1637-42. DOI: 10.1016/j.annonc.2021.08.1994
Published
2024-10-01
How to Cite
1.
Flores Vega YI, Páramo González DL, Perez Fonteboa A, Martínez Ávila DR. Treatment of lung cancer carrier of epidermal growth factor receptor mutation. Rev Cubana Med Milit [Internet]. 2024 Oct. 1 [cited 2025 Jan. 30];53(4):e024044871. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/44871
Issue
Section
Review Article
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
